XVIVO Q3 revenue beats expectations on strong thoracic sales growth
Sweden's XVIVO reported third-quarter sales up 34% year on year, beating analyst expectations, according to Reuters. The company gave no specific guidance for coming periods.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, Swedish medical technology firm XVIVO saw third-quarter sales rise 34% year on year, ahead of analyst forecasts. Thoracic sales climbed 51% in local currencies and were the main driver of growth.
Abdominal sales rose 12%, while service sales fell 28%, partly offsetting gains elsewhere. Adjusted earnings per share reached SEK 1.42, and net income came in at SEK 44.6 million. The company also received a CE certificate for its Heart Assist Transport System.
why it matters
Analysts on average rate the shares a buy, with a median 12-month price target of SEK 330 against an October 21 close of SEK 226.60. The stock trades at about 40 times forward earnings. For markets this is mainly a sector story for Swedish medtech.
market impact
XVIVO and Swedish medtech: strong sales support interest in the sector
tags
instruments
sources
- Sweden's XVIVO Q3 revenue beat expectations on thoracic sales — Reuters, 22 October 2026 at 05:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗